Please login to the form below

Not currently logged in
Email:
Password:

Vascepa

This page shows the latest Vascepa news and features for those working in and with pharma, biotech and healthcare.

Amarin hits jackpot with astonishing heart benefits from fish oil product

Amarin hits jackpot with astonishing heart benefits from fish oil product

Vascepa's effects in patients already treated with statins to lower their LDL cholesterol, who had various cardiovascular risk factors, including persistent elevated trigylcerides. ... patient population with use of Vascepa 4 grams/day as compared to

Latest news

  • Amarin sues FDA over off-label policy Amarin sues FDA over off-label policy

    the risk of heart disease, even though Vascepa itself has not yet been shown to achieve that objective in trials. ... In the meantime Vascepa is bringing in modest sales, with first-quarter turnover of around $15m, albeit up from $11m a year ago.

  • Teva launches first generic of GSK's Lovaza in US Teva launches first generic of GSK's Lovaza in US

    Aside from GSK, the launch of a lower-priced Lovaza generic in the US also impacts Amarin Pharmaceuticals' Vascepa (icosapent ethyl), another fish oil-based therapy that is already on the ... Sales of Vascepa were around $26m in 2013, its first year on

  • Amarin slides as FDA panel votes against fish oil therapy Amarin slides as FDA panel votes against fish oil therapy

    Amarin slides as FDA panel votes against fish oil therapy. Advisory committee wants more data on Vascepa. ... population. By a 9-2 margin, the panel said it would not support approval of the omega-3 fatty acid based Vascepa (icosapent ethyl) as a

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics